-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QEloLnEbuEfvXJn7ZjDZ88zGcMcogcAnGZYaxLHKzfApOWsOW42+GvJ3TYhELujN x6bT6MbjLyDNAlTIxFIIlQ== 0000950133-06-002164.txt : 20060502 0000950133-06-002164.hdr.sgml : 20060502 20060502133001 ACCESSION NUMBER: 0000950133-06-002164 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060331 FILED AS OF DATE: 20060502 DATE AS OF CHANGE: 20060502 EFFECTIVENESS DATE: 20060502 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-06964 FILM NUMBER: 06798490 BUSINESS ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 BUSINESS PHONE: 411724 59 59 MAIL ADDRESS: STREET 1: VODERGASSE 3 STREET 2: SWITZERLAND CITY: SCHAFFHAUSEN STATE: V8 ZIP: CH-8300 13F-HR 1 w20149e13fvhr.txt FORM 13F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 13F Form 13F COVER PAGE Report for Calendar Year or Quarter Ended: March 31, 2006 Check here if Amendment [ ]; Amendment Number: ___________ This Amendment (Check only one.): [ ] is a restatement. [ ] adds new holdings entries. Institutional Investment Manager Filing this Report: Name: BB Biotech AG Address: Vordergasse 3 Schaffhausen Switzerland CH-8200 Form 13F File Number: 28-6964 The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Adrian Bruengger Title: SIGNING AUTHORITY Phone: 41 (01) 267 67 00 Signature, Place, and Date of Signing: /s/ Adrian Bruengger ----------------------------------------- Schaffhausen, Switzerland, May 1, 2006 Report Type (Check only one.): [X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) [ ] 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) [ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) Form 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 4 Form 13F Information Table Entry Total: 21 Form 13F Information Table Value Total: $1,749,311 (thousands)
List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report.
No. Name - --- ------------------- 1 Biotech Focus N.V. 2 Biotech Invest N.V. 3 Biotech Target N.V. 4 Biotech Growth N.V.
BB BIOTECH AG FORM 13F INFORMATION TABLE
COLUMN 5 COLUMN 8 COLUMN 2 COLUMN 4 -------------- COLUMN 6 COLUMN 7 VOTING AUTHORITY COLUMN 1 TITLE OF COLUMN 3 VALUE SHS OR SH/ PUT/ INVESTMENT OTHER ----------------------- NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE -------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ---- Adolor Corp. COM 00724X102 20,547 863,300 SH DEFINED 3 863,300 NONE NONE Affymetrix COM 00826T108 65,860 2,000,000 SH DEFINED 1 2,000,000 NONE NONE Amgen Inc. COM 031162100 90,938 1,250,000 SH DEFINED 1 1,250,000 NONE NONE Anadys Pharmaceuticals COM 03252Q408 32,220 2,000,000 SH DEFINED 3 2,000,000 NONE NONE Arena Pharmaceuticals COM 040047102 18,110 1,000,000 SH DEFINED 3 1,000,000 NONE NONE Biogen Idec Inc. COM 09062X103 258,909 5,497,000 SH DEFINED 1 5,497,000 NONE NONE Celgene Corporation COM 151020104 265,320 6,000,000 SH DEFINED 2 6,000,000 NONE NONE Cephalon COM 156708109 15,605 259,000 SH DEFINED 1 259,000 NONE NONE Elan Corporation, plc COM 284131208 38,988 2,700,000 SH DEFINED 2 2,700,000 NONE NONE Genentech COM 368710406 160,121 1,894,700 SH DEFINED 1 1,894,700 NONE NONE Genzyme Corporation COM 372917104 134,440 2,000,000 SH DEFINED 1 2,000,000 NONE NONE Gilead Sciences, Inc. COM 375558103 219,395 3,526,109 SH DEFINED 1 3,526,109 NONE NONE Incyte Corporation COM 45337C102 18,060 3,000,000 SH DEFINED 3 3,000,000 NONE NONE Keryx Biopharmaceuticals COM 492515101 14,583 763,104 SH DEFINED 3 763,104 NONE NONE Onyx Pharmaceuticals COM 683399109 52,520 2,000,000 SH DEFINED 2 2,000,000 NONE NONE OSI Pharmaceuticals COM 671040103 10,850 338,011 SH DEFINED 2 338,011 NONE NONE Rigel Pharmaceuticals COM 766559603 11,490 1,000,000 SH DEFINED 3 1,000,000 NONE NONE Sepracor Inc. COM 817315104 195,240 4,000,000 SH DEFINED 1 4,000,000 NONE NONE The Medicines Company COM 584688105 62,167 3,022,197 SH DEFINED 3 3,022,197 NONE NONE Vertex Pharamceuticals COM 92532F100 54,922 1,501,000 SH DEFINED 3 1,501,000 NONE NONE Zymogenetics COM 98985T109 9,029 417,602 SH DEFINED 3 417,602 NONE NONE
-----END PRIVACY-ENHANCED MESSAGE-----